Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
480
Trial Sponsor
Trial Collaborator
Clinical Trial Start Date
April 18, 2018
0Primary Completion Date
August 29, 2019
0Study Completion Date
August 29, 2019
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Basic Science0
Intervention Type
Drug0
Intervention Name
LY34718510
Placebo0
Interventional Trial Phase
Phase 10
Official Name
A Phase 1, Double-blind, Randomized, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous NKTR-358 in Patients With Systemic Lupus Erythematosus0
Last Updated
November 18, 2023
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Double0
Masked Party
Investigator0
Participant0
Study summary
The main purpose of this study is to evaluate the safety and tolerability of a study drug known as LY3471851 in participants with SLE. The study will last about 79 days for each participant.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
